Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entera BioENTX -8.41%31 3-Year EBITDA Growth Rate is 17.90% as of Jun. 2026, which is 7% below its 10-year median of 19.35. GuruFocus rates ENTX with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 1,129 Biotechnology companies, Entera Bio ranks better than 53.23% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 17.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Entera Bio was 30.00% per year. The lowest was -48.70% per year. And the median was 19.35% per year.
Entera Bio (NAS:ENTX) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Entera Bio 3-Year EBITDA Growth Rate Related Terms
ENTX vs ICCC, BDTX, COYA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Entera Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Entera Bio's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.90% mean?
Entera Bio (ENTX) has a 3-Year EBITDA Growth Rate of 17.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Entera Bio and its competitors. This is near median its historical median of 19.35. According to the industry distribution chart, Entera Bio ranks #528 out of 1129 companies in the Biotechnology industry, placing it in the top 46.8%.
Is Entera Bio's 3-Year EBITDA Growth Rate too high?
Entera Bio's current 3-Year EBITDA Growth Rate of 17.90% is near median its 10-year median of 19.35. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Entera Bio's value of 17.90% is 20.1% above this industry median. Based on the distribution chart, Entera Bio ranks #528 out of 1129 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Entera Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's 3-Year EBITDA Growth Rate compare to ICCC and BDTX?
According to the Biotechnology industry distribution chart, Entera Bio ranks #528 out of 1129 companies for 3-Year EBITDA Growth Rate. This puts Entera Bio in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Entera Bio's value of 17.90% is 20.1% above this benchmark. While the company's 10-year median is 19.35 vs. the industry median of 14.90, Entera Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entera Bio's current 3-Year EBITDA Growth Rate of 17.90% is 20.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Entera Bio and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entera Bio's current 3-Year EBITDA Growth Rate is 17.90%, which is near median its own 10-year median of 19.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current 3-Year EBITDA Growth Rate of 17.90%. The current 3-Year EBITDA Growth Rate is 17.90%, which is near median its 10-year median of 19.35 and 20.1% above the Biotechnology industry median of 14.90. Entera Bio's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Entera Bio (ENTX), the current 3-Year EBITDA Growth Rate is 17.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
31GF Score
Get the complete analysis for ENTX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENTX has been successfully added to your 
